<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="../../web/xslt/drug-table.xslt"?><drug name = "adalimumab inj SYR>
<dose><value>10</value>
<value>15</value>
<value>20</value>
<value>25</value>
<value>30</value>
<value>35</value>
<value>40</value>
<value>160</value>
<value>80</value>
</dose><route><value>SC</value>
</route><form><value>inj SYR</value>
</form><drug><value>adalimumab inj SYR</value>
</drug><strength><value>40 mg/0.8 mL</value>
</strength><frequency><value>ONCE</value>
<value>EVERY 2 WEEKS</value>
<value>DAILY</value>
</frequency><instruction><value></value>
<value>Administer for 2 days.</value>
</instruction><volume><value></value>
</volume><units><value>mg</value>
</units><additionalnotes><value>Patients identified as carriers of Hepatitis B virus should be monitored for signs/symptoms of relapse of HBV infection throughout therapy and several months following termination of therapy.</value>
</additionalnotes><population><value></value>
</population><indicationprn><value></value>
</indicationprn><backgroundinformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=3607</value>
</backgroundinformation><prninformation><value></value>
</prninformation><ahsformularystatus><value>Formulary with Restrictions.</value>
</ahsformularystatus><ahfsname><value>Disease-modifying Antirheumatic Agents</value>
</ahfsname><highalert><value></value>
</highalert><maximumprndose><value></value>
</maximumprndose></drug>